TARRYTOWN, N.Y., April 23, 2026

Regeneron Pharmaceuticals has achieved a landmark milestone as the U.S. Food and Drug Administration (FDA) granted accelerated approval to Otarmeni™ (lunsotogene parvec-cwha), marking the first and only gene therapy for genetic hearing loss. This breakthrough therapy represents a major leap in genetic medicine, offering a one-time treatment capable of restoring natural hearing in patients with OTOF-related sensorineural hearing loss, a condition historically considered permanent. The approval not only highlights cutting-edge innovation in gene therapy but also underscores Regeneron’s commitment to addressing high unmet medical needs, with the company announcing it will provide the therapy free of cost in the United States for eligible patients.

Clinical Breakthrough with Transformative Outcomes

The FDA approval is based on results from the pivotal CHORD clinical trial, which demonstrated remarkable efficacy and rapid hearing restoration following a single intracochlear dose of Otarmeni. Among participants aged 10 months to 16 years, 80% achieved significant hearing improvement at 24 weeks, meeting the study’s primary endpoint, while 70% showed measurable auditory brainstem responses, confirming restored auditory function.

Notably, 42% of patients achieved normal hearing levels, including the ability to detect whispers, within 48 weeks—an outcome previously unattainable with conventional treatments such as hearing aids or cochlear implants. These results position Otarmeni as a first-in-class therapy capable of restoring neurosensory function to near-normal levels, redefining expectations for genetic hearing loss treatment and offering new hope to affected families worldwide.

Innovative Gene Therapy Mechanism and Safety Profile

Advertisement

cGxPJobs Banner

Otarmeni is an adeno-associated virus (AAV)-based gene therapy designed to deliver a functional copy of the OTOF gene directly into the inner ear, enabling the production of the otoferlin protein, which is essential for sound signal transmission. The therapy is administered through a surgical intracochlear infusion, similar to cochlear implantation, ensuring precise delivery to target cells. Importantly, the therapy utilizes a cell-specific promoter, ensuring gene expression is limited to relevant auditory cells, thereby enhancing safety and effectiveness.

While the treatment demonstrated a favorable safety profile, commonly reported adverse effects included otitis media, dizziness, nausea, and procedural pain, with rare but notable surgical risks such as infection or balance disturbances. Despite these considerations, the overall benefit-risk profile strongly supports its clinical value as a transformative therapeutic option for patients with severe genetic hearing impairment.

Expanding Access and Future of Genetic Medicine

A defining aspect of this approval is Regeneron’s decision to offer Otarmeni at no cost to eligible U.S. patients, setting a new precedent for access to advanced genetic therapies. The therapy has received multiple regulatory designations, including Orphan Drug, Fast Track, Rare Pediatric Disease, and Regenerative Medicine Advanced Therapy (RMAT), emphasizing its significance in addressing a rare and underserved condition affecting approximately 50 newborns annually in the U.S..

Experts believe this approval signals the beginning of a new era in precision medicine, where gene therapies can restore lost biological functions rather than merely manage symptoms. With ongoing global clinical development and planned regulatory submissions, Otarmeni is poised to reshape treatment paradigms for genetic disorders, paving the way for future innovations across multiple therapeutic areas.

Source: Regeneron press release